The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) trial hypothesized that a reduction in xanthine oxidase levels in CHF patients will lead to clinical improvement and a fall in BNP levels at 24 weeks of follow-up. This evidence concerns the gene NPPB and congestive heart failure.